New hope for kids with rare high cholesterol: drug trial launches
NCT ID NCT06597006
First seen Nov 01, 2025 · Last updated May 08, 2026 · Updated 27 times
Summary
This study tests a drug called inclisiran in children aged 2 to under 12 who have a severe inherited form of high cholesterol (homozygous familial hypercholesterolemia). The goal is to see if the drug safely lowers their LDL (bad) cholesterol compared to a placebo over one year, followed by an open-label phase. Only 9 children will take part, and they must already be on standard cholesterol-lowering treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FAMILIAL HYPERCHOLESTEROLEMIA - HOMOZYGOUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Childrens National Hospital
RECRUITINGWashington D.C., District of Columbia, 20010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Novartis Investigative Site
RECRUITINGVienna, 1090, Austria
-
Novartis Investigative Site
RECRUITINGBeijing, Beijing Municipality, 100013, China
-
Novartis Investigative Site
RECRUITINGFrankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
RECRUITINGIoannina, 455 00, Greece
-
Novartis Investigative Site
RECRUITINGThessaloniki, 546 42, Greece
-
Novartis Investigative Site
RECRUITINGKota Bharu, Kelantan, 16150, Malaysia
-
Novartis Investigative Site
RECRUITINGAmsterdam, North Holland, 1105 AZ, Netherlands
-
Novartis Investigative Site
RECRUITINGBloemfontein, Free State, 9301, South Africa
-
Novartis Investigative Site
RECRUITINGTaichung, 407219, Taiwan
-
Novartis Investigative Site
RECRUITINGTaipei, 111045, Taiwan
-
Novartis Investigative Site
RECRUITINGAdana, Saricam, 01330, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGAnkara, Yenimahalle, 06500, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGIzmir, 35100, Turkey (Türkiye)
-
Novartis Investigative Site
RECRUITINGSouthampton, SO16 6YD, United Kingdom
-
UC San Francisco Medical Center
RECRUITINGSan Francisco, California, 94143, United States
-
UC San Francisco Medical Center
RECRUITINGSan Francisco, California, 94143, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Washington Univ School Of Medicine
RECRUITINGSt Louis, Missouri, 63110, United States
Contact
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.